On May 4, Cerebral Co-Founder and Chief Executive Officer Kyle Robertson announced in an email that the company would pause prescribing controlled substances such as Adderall to treat ADHD in new patients. The pause will go into effect on May 9.
The announcement comes as telehealth startups like Cerebral began facing scrutiny from pharmacies across the country who have expressed concerns that these startups’ clinicians are writing too many prescriptions for Adderall and other stimulants.
Cerebral’s preferred pharmacy partner, Truepill Inc., stopped filling prescriptions for stimulants when a former executive filed a lawsuit alleging the company put growth before patient safety.
In May, former Cerebral employees told Bloomberg the company could be fueling a new addiction crisis because providers are pressured to prescribe medications after short video visits.
Cerebral said prescription delays occurred because of confusion around telehealth policies, and that it doesn’t pressure its clinicians to prescribe stimulants.
The company also said the allegations in the employee lawsuit were false and that it would defend itself.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.